Published in Gastroenterology on March 02, 2011
I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Res (2015) 0.85
Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int (2013) 0.82
Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol (2014) 0.82
The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr (2015) 0.81
Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. World J Gastroenterol (2015) 0.77
Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials. PLoS One (2016) 0.76
Coffee and Liver Disease. J Clin Exp Hepatol (2016) 0.75
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
Coffee intake linked to improved SVR in patients undergoing treatment for hepatitis C. Ann Gastroenterol (2011) 0.75
Coffee and liver - long way to go. J Clin Exp Hepatol (2012) 0.75
Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B. Nutrients (2017) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
The global burden of hepatitis C. Liver Int (2009) 8.89
Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol (1990) 8.70
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA (2005) 4.14
Comparison of two dietary questionnaires validated against multiple dietary records collected during a 1-year period. J Am Diet Assoc (1992) 3.91
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology (2005) 3.47
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology (2007) 3.22
Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol (2008) 2.98
Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med (2009) 2.79
Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology (2007) 2.57
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology (2010) 2.53
Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol (2001) 2.03
Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med (2006) 1.90
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2005) 1.76
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology (2010) 1.59
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2010) 1.58
Hepatitis C in African Americans: summary of a workshop. Gastroenterology (2000) 1.32
Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol (1998) 1.31
Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet (2009) 1.31
Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol (1993) 1.25
Coffee consumption and serum aminotransferases in middle-aged Japanese men. J Clin Epidemiol (2001) 1.13
The Tromsø Heart Study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scand J Clin Lab Invest (1986) 1.13
Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13
Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol (2004) 1.12
Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol (2008) 1.01
Nuclear factor-kappaB/signal transducers and activators of transcription-1-mediated inflammatory responses in lipopolysaccharide-activated macrophages are a major inhibitory target of kahweol, a coffee diterpene. Biol Pharm Bull (2010) 0.86
Coffee intake and chronic hepatitis C. Hepatology (2009) 0.77
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Association of coffee drinking with total and cause-specific mortality. N Engl J Med (2012) 5.31
Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr (2008) 5.01
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2003) 4.95
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
The prevalence of celiac disease in the United States. Am J Gastroenterol (2012) 4.77
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Prevalence of estimated GFR reporting among US clinical laboratories. Am J Kidney Dis (2008) 3.55
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol (2007) 3.30
Meat consumption and risk of colorectal cancer. JAMA (2005) 3.15
Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology (2005) 3.12
Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology (2014) 3.04
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst (2013) 2.76
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab (2011) 2.73
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology (2008) 2.63
Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol (2003) 2.60
Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol (2005) 2.51
A prospective study of red and processed meat intake in relation to cancer risk. PLoS Med (2007) 2.49
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A (2004) 2.30
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer (2004) 2.25
Meat-related mutagens/carcinogens in the etiology of colorectal cancer. Environ Mol Mutagen (2004) 2.22
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology (2003) 2.14
Activity energy expenditure and incident cognitive impairment in older adults. Arch Intern Med (2011) 2.07
Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med (2007) 2.07
Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology (2013) 2.03
A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res (2006) 2.02
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology (2011) 2.01
A large prospective study of meat consumption and colorectal cancer risk: an investigation of potential mechanisms underlying this association. Cancer Res (2010) 1.98
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet (2003) 1.95
Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol (2013) 1.95
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Trends in meat consumption in the USA. Public Health Nutr (2010) 1.89
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
Associations of body mass index, smoking, and alcohol consumption with prostate cancer mortality in the Asia Cohort Consortium. Am J Epidemiol (2015) 1.87
Genomic methylation of leukocyte DNA in relation to colorectal adenoma among asymptomatic women. Gastroenterology (2007) 1.83
Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort. J Natl Cancer Inst (2010) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2005) 1.76
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology (2010) 1.67
A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res (2005) 1.63
Meat intake and cause-specific mortality: a pooled analysis of Asian prospective cohort studies. Am J Clin Nutr (2013) 1.61
Large prospective investigation of meat intake, related mutagens, and risk of renal cell carcinoma. Am J Clin Nutr (2011) 1.60
Epidemiology of nonalcoholic fatty liver. Clin Liver Dis (2004) 1.59
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med (2003) 1.58
Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol (2002) 1.57
Meat intake and cooking techniques: associations with pancreatic cancer. Mutat Res (2002) 1.57
A prospective investigation of coffee drinking and endometrial cancer incidence. Int J Cancer (2011) 1.56
Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One (2011) 1.55
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52